Literature DB >> 6217246

IgE-binding factors from mouse T lymphocytes. I. Formation of IgE-binding factors by stimulation with homologous IgE and interferon.

T Uede, K Sandberg, B R Bloom, K Ishizaka.   

Abstract

Incubation of normal mouse spleen cells with homologous IgE resulted in the formation of soluble factors that inhibited rosette formation of mouse Fc epsilon R+ cells with IgE-coated ox erythrocytes. The soluble factors could be absorbed with mouse or rat IgE coupled to Sepharose and recovered from the beads by acid elution. However, the factors had no affinity for either human IgE or mouse IgG. The IgE-binding factors were derived from T cells. Production of the factors required Lyt1+ T cells and Fc gamma R+ cells, which suggests that the factors are derived from Fc gamma R+ Lyt 1+ T cells. The molecular size of IgE-binding factors was approximately 15,000 daltons. When IgE-binding factors were formed by BALB/c spleen cells, nearly one-half of the factors had affinity for lentil lectin, and the remaining half of the factors failed to bind to the lectin. The proportion of the two species of IgE-binding factors differed depending on mouse strains. The majority of the factors formed by B6D2F1 spleen cells had affinity for lentil lectin, but those formed by SJL spleen cells failed to bind to the lectin. The IgE-binding factors were also induced by incubation of normal spleen cells with polyinosinic-polycytidylic acid (pI:pC). The nucleotide stimulated splenic adherent cells to form "inducers" of IgE-binding factors, which in turn induced normal lymphocytes to form IgE-binding factors. The inducers of IgE-binding factors were inactivated (or neutralized) by antibodies specific for mouse Type I interferon. It was also found that purified mouse beta interferon could induce the formation of IgE-binding factors. IgE-binding factors induced by pI:pC consisted of two different molecules: one had a m.w. of 15,000 daltons, and another had a m.w. of between 40,000 and 60,000 daltons.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6217246

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Regulation of IgE synthesis. Lymphocyte Fc epsilon receptor, IgE binding factor(s), and glycosylation-modulating factors.

Authors:  J Yodoi; T Kawabe; M Takami
Journal:  Clin Rev Allergy       Date:  1989

2.  Induction of Fc epsilon receptors on normal murine T cells and IgE binding factor(s) by cross-linked IgE or IgE-pulsed adherent cells.

Authors:  M A Firer; Z Eshhar
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

Review 3.  Control of IgE synthesis in man.

Authors:  D Y Leung; R S Geha
Journal:  J Clin Immunol       Date:  1986-07       Impact factor: 8.317

4.  Lack of Fc receptor for IgE in SJA9 mice.

Authors:  M Adachi; K Okumura; N Watanabe; N Noro; T Masuda; J Yodoi
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

Review 5.  Fc receptor--more answers, more questions.

Authors:  L Fornůsek; V Vĕtvicka
Journal:  Folia Microbiol (Praha)       Date:  1984       Impact factor: 2.099

6.  Association of I-J determinants with lipomodulin/macrocortin.

Authors:  P Jardieu; M Akasaki; K Ishizaka
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

7.  Studies on in vitro IgE synthesis from lymph node cells of mice during infection with Nippostrongylus brasiliensis. Presence of inhibitory factor(s) in serum.

Authors:  P Pfeiffer; I Rauschen; W König
Journal:  Parasitol Res       Date:  1987       Impact factor: 2.289

8.  Isotype-specific immunoregulation. IgA-binding factors produced by Fc alpha receptor-positive T cell hybridomas regulate IgA responses.

Authors:  H Kiyono; L M Mosteller-Barnum; A M Pitts; S I Williamson; S M Michalek; J R McGhee
Journal:  J Exp Med       Date:  1985-04-01       Impact factor: 14.307

9.  IgE-antigen complexes enhance Fc epsilon R and Ia expression by murine B lymphocytes.

Authors:  M L Richards; J F Marcelletti; D H Katz
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.